Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2026)

Bristol Myers Squibb has disclosed Change in Accured Expenses across 6 years of filings, most recently posting -$3.5 billion for Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 457.42% year-over-year to -$3.5 billion; the TTM figure through Mar 2026 stood at -$3.3 billion (down 317.41% YoY), while the FY2025 annual figure was -$441.0 million, down 129.72% from the prior year.
• Change in Accured Expenses retreated to -$3.5 billion in Q1 2026, from -$2.4 billion in the prior quarter.
• Over the last five years, Change in Accured Expenses for BMY reached as high as $1.8 billion in Q3 2024 and fell as low as -$3.5 billion in Q1 2026.
• The 5-year median for Change in Accured Expenses is -$211.0 million (2023), against an average of -$65.9 million.
• The widest YoY moves for Change in Accured Expenses: up 141.86% in 2022, down 676.92% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at -$303.0 million in 2022, then soared by 30.36% to -$211.0 million in 2023, then tumbled by 91.94% to -$405.0 million in 2024, then sank by 492.1% to -$2.4 billion in 2025, then tumbled by 45.75% to -$3.5 billion in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$3.5 billion, -$2.4 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.